购物车
- 全部删除
- 您的购物车当前为空
HPN Protein, Human, Recombinant (His) is expressed in HEK293 mammalian cells with C-His tag. The predicted molecular weight is 42 kDa and the accession number is P05981.
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
100 μg | ¥ 2,960 | 5日内发货 | |
500 μg | ¥ 11,800 | 5日内发货 | |
1 mg | ¥ 19,700 | 5日内发货 |
生物活性 | Immobilized Human HPN, His Tag at 2μg/ml (100μl/Well) on the plate. Dose response curve for Anti-HPN Antibody, hFc Tag with the EC50 of 10.4ng/ml determined by ELISA. |
产品描述 | HPN Protein, Human, Recombinant (His) is expressed in HEK293 mammalian cells with C-His tag. The predicted molecular weight is 42 kDa and the accession number is P05981. |
种属 | Human |
表达系统 | HEK293 Cells |
标签 | C-His |
蛋白编号 | P05981 |
别名 | TMPRSS1,HX,Hpxn,HPX,HPN,Hepsin,Hemopexin,FLJ56652 |
蛋白构建 | Arg45-Leu417 |
蛋白纯度 | > 95% as determined by Tris-Bis PAGE; > 95% as determined by HPLC |
分子量 | 42 kDa (predicted). Due to the protein cleaved into the following two chains, so it migrates to 18-22 kDa and 30 kDa based on Tris-Bis PAGE result. |
内毒素 | < 1 EU/μg by the LAL method. |
缓冲液 | Lyophilized from a solution filtered through a 0.22 μm filter, containing 20 mM NaAc, 150 mM NaCl (pH 5.0). Typically, 8% trehalose is incorporated as a protective agent before lyophilization. |
复溶方法 | Reconstitute the lyophilized protein in 20mM NaAc,150mM NaCl (pH 5.0). The product concentration should not be less than 100 μg/ml. Before opening, centrifuge the tube to collect powder at the bottom. After adding the reconstitution buffer, avoid vortexing or pipetting for mixing. |
存储 | It is recommended to store recombinant proteins at -20°C to -80°C for future use. Lyophilized powders can be stably stored for over 12 months, while liquid products can be stored for 6-12 months at -80°C. For reconstituted protein solutions, the solution can be stored at -20°C to -80°C for at least 3 months. Please avoid multiple freeze-thaw cycles and store products in aliquots. |
运输方式 | In general, Lyophilized powders are shipping with blue ice. |
研究背景 | Home parenteral nutrition (HPN) has been proposed as the treatment of choice in patients suffering from intestinal failure (IF) and has been claimed to improve survival and quality of life either in patients with benign disorders or even in those with malignancies. HPN seems to have beneficial effect but it should be considered with caution by the physicians who should take into account the indications of each patient to receive parenteral nutrition, the underlying disease and prognosis and the access of each patient to home care services. |
版权所有©2015-2024 TargetMol Chemicals Inc.保留所有权利.